AGP Executive Report
Last update: 8 hours agoGLP-1 Oversight Under Scrutiny: A secret shopper study found many GLP-1 telehealth sites move fast with little clinician oversight, sometimes issuing prescriptions in minutes and mailing compounded or branded meds despite missing or inconsistent patient details. Pipeline Pressure at Novo: Novo Nordisk’s CEO framed innovation as “survival” after a late-stage setback for ziltivekimab, signaling renewed focus on early pipeline bets. Big Pharma Deal Talk Meets Regulatory Reality: Rumors of a potential Bristol Myers Squibb–AstraZeneca merger surfaced amid Q2 earnings, with analysts flagging antitrust hurdles. Supply Chain & Manufacturing Moves: Medline reported strong med-surg growth and updated guidance; Lifecore Biomedical highlighted new late-stage pipeline wins; and Fujifilm and Taiho partnered to strengthen next-gen ADC manufacturing. Cancer & CNS Development: FDA breakthrough status was granted to Lilly’s pancreatic cancer drug olomorasib, while Supernus and Indivior announced a merger to build a CNS-focused company. Policy & Access: New Jersey proposed a multistate settlement over alleged generic drug price-fixing, and California’s Supreme Court ruled Gilead had no duty to bring a newer HIV drug to market sooner.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27281720-931994693-d7979a1cc9913d6d8acc1dd509405c75456eb97e-8101x5401-100x67.jpeg)
![<![CDATA[CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27281499-931994801-2d63e712a1f2cc158ae4f7ee42d3e3351ef105ec-1280x720-100x56.jpeg)
![[Latest] Global Generative AI In Clinical Trials Market Size/Share Worth USD 1.86 Billion by 2035 at a 9.63% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/21273967-731329129-cmi-logo-png-100x51.png){kind=logo}
